Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT– la « Société »), entreprise biopharmaceutique au stade clinique qui développe...
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative...
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug...
Annual General Meeting to be held on September 13, 2024, to approve the financial statements for the year ending December 31, 2023 Update on the...
Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société...
Nouvelles analyses de l’étude de phase 2/3 ACTISAVE démontrant des tendances favorables pour le glenzocimab sur des sous-populations de patients...
Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.